CureVac may let contractors make rival vaccines if own shot fails -CEO



© Reuters. FILE PHOTO: A volunteer receives a dose of CureVac vaccine or a placebo during a study by the German biotech firm CureVac as part of a testing for a new vaccine against the coronavirus disease (COVID-19), in Brussels, Belgium March 2, 2021. REUTERS/Yves H

By Tilman Blasshofer and Ludwig Burger

FRANKFURT (Reuters) – German biotech firm CureVac could allow its network of manufacturing partners to be repurposed to make vaccines developed by other companies should its own experimental shot fail, its chief executive told Reuters on Thursday.

The German company saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47% effective in an initial trial read-out, denting investor confidence in its ability to take on rival shots.

“At the moment we are of course fully committed to obtain authorisation, the data will show,” CureVac CEO Franz-Werner Haas told Reuters TV, referring to a final read-out that is still pending.

“If this capacity is not to be used – we are working with a whole network of outstanding partners – … these partners would of course be free to make other products if we don’t have a product,” he said.

CureVac’s manufacturing partners include Celonic Group of Switzerland, Novartis, Bayer (DE:), Fareva, Wacker and Rentschler Biopharma SE.

However, Haas stressed that CureVac’s efforts to develop a new generation of vaccines, a venture where it collaborates with GlaxoSmithKline, would take precedence and that he would continue to draw on the external contractors for that drive

Drug supply chain expert Prashant Yadav said that if CureVac’s partners were to make different mRNA vaccine, like Pfizer-BioNtech’s or Moderna (NASDAQ:)’s, it would take at least six to eight weeks to retool their facilities.

See also  Alphabet A Earnings, Revenue beat in Q1

Yadav suggested that the Pfizer-BioNTech vaccine might be a better candidate, given that BioNTech is in Germany and many of CureVac’s manufacturing partners are in Germany and Austria.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.





READ SOURCE

LEAVE A REPLY

Please enter your comment!
Please enter your name here